1. Mahdavi MA, Mehrabi YA, Khalili DA, Baghestani AR, Bagherzadeh-Khiabani F, Mansouri SA. Factors associated with incidence of type II diabetes in pre-diabetic women using Bayesian Model Averaging. Koomesh 2017;19(3). [
Google Scholar]
2. Nematollahi M, Jafari A, Arabian S, Mohammadbeigi A, University of Medical Sciences, Shiraz, University of Medical Sciences, Shiraz, et al. Cost-effectiveness analysis of hospital information system in comparison with manual system in selected sections of Namazi hospital of Shiraz. J Health 2020;11(1): 25-36. https: //doi.org/10.29252/j.health.11.1.25 [
DOI:10.29252/j.health.11.1.25]
3. Bakhshayesh Karam M, Dabbaghmanesh AR, Dabbaghmanesh MH, Ranjabar Omrani G. Precipitating Factors, Biological Characteristics and Clinical Manifestations in Patients Admitted With Diabetic Ketoacidosis in Shiraz Nemazee Hospital. Iran J Endocrinol Metabol 2013;14(6): 531-7. [
Google Scholar]
4. Cashen K, Petersen T. Diabetic ketoacidosis. Pediatr Rev 2019;40(8): 412-20. https: //doi.org/10.1542/pir.2018-0231 [
DOI:10.1542/pir.2018-0231] [
PMID]
5. Sheikholeslami H, Ziaee A, Shariatmadari M. Evaluation of clinical manifestation, laboratory data and precipitating factors in patients with Diabetic ketoacidosis in educational and medical care center of Booali Sina in Ghazvin (1999-2004). J Birjand Univ Med Sci 2008;15(2): 60-4. [
URL]
6. DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet 2018;391(10138): 2449-62. https: //doi.org/10.1016/S0140-6736(18)31320-5 [
DOI:10.1016/S0140-6736(18)31320-5] [
PMID]
7. Aligholipour M, Feizollahzadeh H, Ghaffari M, Jabbarzadeh F. The effect of in-person and multimedia short message based education in telegram on fasting blood glucose and glycosylated hemoglobin in patients with insulin-dependent diabetes. I Iran J Diabetes Metabol 2019;18(2): 64-70. [
Google Scholar]
8. Chang X, Jørgensen AMM, Bardrum P, Led JJ. Solution structures of the R6 human insulin hexamer. Biochemistry 1997;36(31): 9409-22. https: //doi.org/10.1021/bi9631069 [
DOI:10.1021/bi9631069] [
PMID]
9. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(5): 1047-54. https: //doi.org/10.2337/diacare.27.5.1047 [
DOI:10.2337/diacare.27.5.1047] [
PMID]
10. Galloway J, Spradlin C, Nelson R, Wentworth S, Davidson J, Swarner J. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care 1981;4(3): 366-76. https: //doi.org/10.2337/diacare.4.3.366 [
DOI:10.2337/diacare.4.3.366] [
PMID]
11. Hsia E, Seggelke S, Gibbs J, Hawkins RM, Cohlmia E, Rasouli N, et al. Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia. J Clin Endocrin Metabol 2012;97(9): 3132-7. https: //doi.org/10.1210/jc.2012-1244 [
DOI:10.1210/jc.2012-1244] [
PMID]
12. Vincent M, Nobécourt E. Treatment of diabetic ketoacidosis with subcutaneous insulin lispro: a review of the current evidence from clinical studies. Diabetes Metab 2013;39(4): 299-305. https: //doi.org/10.1016/j.diabet.2012.12.003 [
DOI:10.1016/j.diabet.2012.12.003] [
PMID]
13. Yismaw BF, Leulseged TW. Subcutaneous regular insulin use for the management of diabetic ketoacidosis in resource limited setting. J Pediatr Endocrinol Metab 2022;35(2): 179-84. https: //doi.org/10.1515/jpem-2021-0527 [
DOI:10.1515/jpem-2021-0527] [
PMID]
14. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343(oct18 2): d5928. https: //doi.org/10.1136/bmj.d5928 [
DOI:10.1136/bmj.d5928] [
PMID] [
]
15. Umpierrez GE, Cuervo R, Karabell A, Latif K, Freire AX, Kitabchi AEJDc. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care 2004;27(8): 1873-8. https: //doi.org/10.2337/diacare.27.8.1873 [
DOI:10.2337/diacare.27.8.1873] [
PMID]
16. Umpierrez GE, Latif K, Stoever J, Cuervo R, Park L, Freire AX, et al. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. Am J Med 2004;117(5): 291-6. https: //doi.org/10.1016/j.amjmed.2004.05.010 [
DOI:10.1016/j.amjmed.2004.05.010] [
PMID]
17. Della Manna T, Steinmetz L, Campos PR, Farhat SC, Schvartsman Cu, Kuperman H, et al. Subcutaneous use of a fast-acting insulin analog: an alternative treatment for pediatric patients with diabetic ketoacidosis. Diabetes Care 2005;28(8): 1856-61. https: //doi.org/10.2337/diacare.28.8.1856 [
DOI:10.2337/diacare.28.8.1856] [
PMID]
18. Ersöz H, Ukinc K, Köse M, Erem C, Gunduz A, Hacihasanoglu A, et al. Subcutaneous lispro and intravenous regular insulin treatments are equally effective and safe for the treatment of mild and moderate diabetic ketoacidosis in adult patients. Int J Clin Pract 2006;60(4): 429-33. https: //doi.org/10.1111/j.1368-5031.2006.00786.x [
DOI:10.1111/j.1368-5031.2006.00786.x] [
PMID]
19. Karoli R, Fatima J, Salman T, Sandhu S, Shankar RJIJoP. Managing diabetic ketoacidosis in non-intensive care unit setting: role of insulin analogs. Ind J Pharmacol 2011;43(4): 398. https: //doi.org/10.4103/0253-7613.83109 [
DOI:10.4103/0253-7613.83109] [
PMID] [
]
20. Sangey ED. Comparing the efficacy of subcutaneous intermittent soluble insulin versus intravenous continuous soluble insulin infusion in the treatment of diabetic ketoacidosis in an emergency department setting: Muhimbili University of Health and Allied Sciences.; 2013.
21. Shalash MM, Rahim AA, Rohoma KH, Elnabawy A. The Utility of Continuous Subcutaneous Insulin Infusion for Management of Mild to Moderate Diabetic Ketoacidosis. Am Intern Med 2016;4(3): 43-8. https: //doi.org/10.11648/j.ajim.20160403.11 [
DOI:10.11648/j.ajim.20160403.11]
22. Balili CAV, Gomez MHSJPJIM. Efficacy and safety of subcutaneous insulin analogue versus intravenous insulin infusion among patients with mild to moderate diabetic ketoacidosis at the university of Santo Tomas hospital. Phillippine J Internal Med 2017;55(1). [
Google Scholar]
23. Razavi Z, Maher S, Fredmal J. Comparison of subcutaneous insulin aspart and intravenous regular insulin for the treatment of mild and moderate diabetic ketoacidosis in pediatric patients. Endocrine 2018;61(2): 267-74. https: //doi.org/10.1007/s12020-018-1635-z [
DOI:10.1007/s12020-018-1635-z] [
PMID]
24. Andrade-Castellanos CA, Colunga-Lozano LE. Systematic review with meta-analysis: Subcutaneous insulin glargine coadministration for diabetic ketoacidosis. Gac Med Mex. 2016;152(6): 761-9. [
Google Scholar]
25. Forestell B, Battaglia F, Sharif S, Eltorki M, Samaan MC, Choong K, et al. Insulin infusion dosing in pediatric diabetic ketoacidosis: A systematic review and meta-analysis of randomized controlled trials. Crit Care Explor 2023;5(2): e0857. https: //doi.org/10.1097/CCE.0000000000000857 [
DOI:10.1097/CCE.0000000000000857] [
PMID] [
]
26. Kolb H, Kempf K, Röhling M, Martin S. Insulin: too much of a good thing is bad. BMC Med 2020;18(1): 224. https: //doi.org/10.1186/s12916-020-01688-6 [
DOI:10.1186/s12916-020-01688-6] [
PMID] [
]
27. Alshurtan KS, Alnizari O, Aldarwish H, Al-Tufaif AA. Efficacy and safety of intravenous insulin in treatment of patient with diabetic ketoacidosis: A systematic review and meta-analysis. Cureus [Internet]. 2022;14(10): e30721. https: //doi.org/10.7759/cureus.30721 [
DOI:10.7759/cureus.30721] [
PMID] [
]